May 31, 2024

Children most vulnerable to thirdhand smoke: Experts

Children are most vulnerable to third-hand smoke pollutants that settle indoors when tobacco is smoked, said health experts on Thursday, ahead of World No Tobacco Day.

World No Tobacco Day is observed every year on May 31 to raise awareness about the health risks of using tobacco.

Thirdhand smoke contains more than 250 residual chemicals including nicotine and cancer-causing substances such as formaldehyde, and naphthalene. It builds up on surfaces over time and can get embedded in clothing, furniture, drapes, bedding, and carpets.

"Children are most vulnerable to thirdhand smoke because they tend to touch surfaces, and often their mouths, resulting in skin exposure and ingestion of these residues," Lancelot Mark Pinto, from P. D. Hinduja Hospital & MRC, Mumbai, told IANS.

"The only way to prevent such exposure is by completely banning indoor smoking, and insisting on keeping a radius outside buildings and homes smoke-free," added Lancelot, Consultant Pulmonologist and Epidemiologist at Hinduja.

Thirdhand smoke is a hidden danger, lingering in furniture, walls, and clothing long after a cigarette is extinguished. The residue can remain for weeks, months, or even years.

"Vulnerable groups include infants, children, and those with respiratory conditions, as they are more likely to come into contact with these contaminated surfaces and inhale harmful residues," Ishan Capoor, pulmonologist and respiratory medicine, Narayana Health City, Bengaluru, told IANS.

"This exposure can lead to respiratory issues, developmental problems, and an increased risk of cancer," he added.

To prevent third-hand smoke exposure, ensure that smoking is strictly prohibited indoors and in vehicles. Regularly clean surfaces and fabrics, and encourage smokers to quit or at least to smoke outside and away from others. Awareness and proactive measures are essential to protect the health of those most at risk."

In addition to children, Srinath Bharadwaj, Medical Oncologist at Apollo Cancer Centre, Jubilee Hills, Hyderabad, told IANS that it may also harm pets in the house.

"Our furry friends usually groom by licking their fur. If that fur is coated with smoke residue, they ingest carcinogens and toxins on top of the ones their lungs take in," he said.

The experts called on businesses, communities, and individuals to take action to help prevent thirdhand smoke exposure by not allowing smoking indoors. Smoking in front of an open window does not prevent thirdhand smoke exposure.

"The best way is to quit smoking and stay safe and keep your family safe," they noted.

https://www.newkerala.com/news/2024/30842.htm

Over 46 pc young adults quit tobacco in India, UP leads: Report

About 46.96 per cent of young adults, aged 18-24, have quit tobacco in India, according to a report on Thursday by Vallabhbhai Patel Chest Institute (VPCI) based on a survey of calls received by the government’s National Tobacco QuitLine Services (NTQLS).

World No Tobacco Day is observed every year on May 31. The VPCI survey based on NTQLS data showed that the tobacco quitline recorded 1,44,938 quitters from 4,77,585 registered calls, with a total of 8.2 million calls hitting the interactive voice response (IVR) between May 2016 and April 2024.

A total of 46.96 per cent of registered calls to the NTQLS were from 18-24-year-olds, who also had a 12th-grade education -- making them the largest group of quitters.

“This data highlights the growing awareness and determination among India’s youth to combat tobacco addiction,” the VPCI said.

Over 43 per cent reported to be self-employed, 75.85 per cent had no family history of tobacco use, while 68.63 per cent were found to use smokeless tobacco.

Further, the data showed that Uttar Pradesh led with 1,50,925 (31.6 per cent) calls and 29.68 per cent of quitters. In addition, 72.96 per cent of calls were made from individuals with 1-10 years of tobacco use, and 77.74 per cent have no history of alcohol use.

“The NTQLS provides free, confidential counselling and guidance to tobacco users across the country, empowering them to take charge of their health,” said Dr. Raj Kumar, Director, Vallabhbhai Patel Chest Institute.

“Quitting tobacco is not just about willpower. We address the psychological and behavioural factors that contribute to addiction, offering strategies to manage cravings and overcome withdrawal symptoms," added Dr. Raj, leading the Tobacco Cessation Clinic (TCC) at VPCI since November 2001.

Over the past 23 years, TCC at VPCI has organised 376 public awareness programmes, anti-tobacco campaigns, and seminars, reaching over 1.3 million people.

These initiatives have trained 57,243 doctors, benefited 44,652 students, and empowered 61,129 social workers, creating a ripple effect of awareness and education.

https://www.newkerala.com/news/2024/30899.htm

411 million adult tobacco users in SE Asia, highest globally: WHO

The Southeast Asia region, which includes India, has about 411 million adult tobacco users -- the highest globally, said Saima Wazed, WHO Regional Director on Thursday on the eve of World No Tobacco Day.

Observed every year on May 31, World No Tobacco Day was designated in 1987, by Member States of the World Health Organization (WHO) to draw attention to the global tobacco epidemic, and the preventable death and disease it causes.

"The fight against tobacco is particularly important for us in South-East Asia. The tobacco industry's targeting of youth is rampant across our Member States. As a result, we have a very worrying 11 million adolescents using various tobacco products," Saima Wazed said in a statement.

"Coupled with the approximate 411 million adult tobacco users, our region, unfortunately, has the highest number of adolescent and adult users globally," she added.

The theme this year is "protecting children from tobacco industry interference".

Saima Wazed lamented that it is "worrying" that the "industry lures youth by aggressively introducing new nicotine and tobacco products such as electronic cigarettes and heated tobacco products".

"Young people across the world are calling for the tobacco industry to stop targeting them with products that are harmful to their health."

She said that governments must adopt policies to protect them from the manipulative practices of tobacco and related industries, which includes the relentless marketing of their dangerous products through social media and streaming platforms.

Despite having policies and regulations in place, these are becoming increasingly popular with the youth in the SE Asia region, and "social media and other similar platforms are likely to make this worse".

"The tobacco industry moves with speed to launch new products, using every means to expand market share before regulations can catch up," the WHO Regional Director said.

"They continue to oppose evidence-based measures, such as increases in excise taxes, and comprehensive bans on tobacco advertising, promotions, and sponsorships. They even threaten legal action against governments that try to protect the health of their citizens."

She pointed out the "lagging" efforts by governments and institutions to fight the marketing strategies of the tobacco industry.

The WHO chief called for a generational tobacco ban, leading to a 'Tobacco-Free Generation'.

"Our goal for our youth is clear. We want to prevent and reduce tobacco consumption, nicotine addiction, and exposure to new tobacco products."

https://www.newkerala.com/news/2024/30908.htm

Study reveals key protein that helps prevent excessive bone loss in osteoporosis

Osteoporosis, a disorder characterised by porous and weak bones, is a major hazard to skeletal health. As the foundation of the human body, bones provide critical structural support. When bone mass decreases, it not only weakens this support but also lowers general function, resulting in a lower quality of life.

With an ageing population and a rise in osteoporosis cases, the burden on healthcare resources for long-term care is clear. As a result, there is a need to understand the mechanisms that cause osteoporosis and develop effective targeted therapeutics to mitigate its long-term effects.

Osteoblasts and osteoclasts are two types of cells that play critical roles in bone tissue maintenance and remodelling. Osteoblasts are bone-forming cells that synthesise and deposit new bone tissue, whereas osteoclasts break down and remove old or damaged bone tissue. Increased proportion of osteoclasts causes bone mass loss in situations such as osteoporosis, rheumatoid arthritis (joint inflammation), and bone metastases (cancer that has spread to the bones). Osteoclasts develop from the development of macrophages or monocytes, two types of immune cells. Suppressing osteoclast differentiation could thus be used as a therapeutic technique to prevent bone loss. However, the precise molecular pathways driving the complicated process of bone remodelling are unknown.

In a new groundbreaking study, Professor Tadayoshi Hayata, Mr. Takuto Konno, and Ms. Hitomi Murachi from Tokyo University of Science, along with their co-workers, delved deeper into the molecular regulation of osteoclast differentiation. Receptor activator of nuclear factor kappa B ligand (RANKL) stimulation induces the differentiation of macrophages into osteoclasts. Further, bone morphogenetic protein (BMP) and transforming growth factor (TGF)-b signaling pathways have been implicated in the regulation of RANKL-mediated osteoclast differentiation. In the current study, the researchers sought to investigate the role of Ctdnep1 - a phosphatase (an enzyme that removes phosphate groups) that has been reported to suppress BMP and TGF-b signaling.

Giving further insight into their work set to be published on July 30, 2024, in Volume 719 of Biochemical and Biophysical Research Communications, Prof. Hayata states, "RANKL functions as an 'accelerator' for osteoclast cell differentiation. Driving a car requires not only the accelerator but also the brakes. Here, we find that Ctdnep1 functions as a 'brake' on osteoclast cell differentiation."

First, the researchers examined the expression of Ctdnep1 in mouse-derived macrophages treated with RANKL and untreated control cells. They noted that Ctdnep1 expression remained unchanged in response to RANKL stimulation. However, it localized in the cytoplasm in granular form in the macrophages and differentiated into osteoclasts, distinct from its normal peri-nuclear localization in other cell types, indicating its cytoplasmic function in osteoclast differentiation.

Further, Ctdnep1 knockdown (downregulation of gene expression) resulted in an increase in tartrate-resistant acid phosphatase-positive (TRAP) osteoclasts; wherein TRAP is a marker for differentiated osteoclasts. Additionally, Ctdnep1 knockdown led to an increase in the expression of crucial differentiation markers including 'Nfatc1', a RANKL-induced master transcription factor for osteoclast differentiation. These results support the 'brake function' of Ctdnep1, whereby, it negatively regulates osteoclast differentiation.

Moreover, Ctdnep1 knockdown also led to increased absorption of calcium phosphate, suggestive of the suppressive role of Ctdnep1 in bone resorption. Lastly, while, Ctdnep1 knockdown did not alter BMP and TGF-b signaling, cells deficient in Ctdnep1 showed elevated levels of phosphorylated (activated) proteins downstream of the RANKL signaling pathway. These findings suggest that the suppressive effect of Ctdnep1 in osteoclast differentiation may not be mediated by BMP and TGF-b signaling, but, through the negative regulation of RANKL signaling and Nfatc1 protein levels.

Overall, these findings provide novel insights into the process of osteoclast differentiation and reveal potential therapeutic targets which can be pursued to develop treatments that address bone loss due to excessive osteoclast activity. In addition to diseases characterized by bone loss, Ctdnep1 has also been reported as a causative factor in medulloblastoma - a childhood brain tumor. The authors are, therefore, optimistic that their research can be extended to other human diseases beyond bone metabolism.

https://www.newkerala.com/news/2024/30939.htm

Researchers find how better sleep is linked to lower levels of loneliness

A recent study discovered that greater sleep health was linked to lower levels of loneliness, with the association being stronger among younger persons.

The findings of the study were presented at the SLEEP 2024 annual meeting.

The findings show that higher sleep health is related with significantly lower total loneliness, emotional loneliness, and social loneliness. Better sleep health was associated with lower total and emotional loneliness across all ages, however this association was higher in younger persons. However, age did not influence the relationship between sleep health and social loneliness.

"Loneliness is an urgent public health crisis, and there is a pressing need for providers to better understand and treat it," said lead author and principal investigator Joseph Dzierzewski, who has a doctorate in clinical psychology and is vice president of research at the National Sleep Foundation in Washington, D.C. "Our results highlight the important role that sleep plays in understanding loneliness across the adult lifespan. Perhaps efforts to improve sleep health could have a beneficial effect on loneliness, especially for young people."

According to the American Academy of Sleep Medicine, sleep is essential to health. The AASM and the Sleep Research Society recommend that adults should sleep seven hours per night on a regular basis to promote optimal health, productivity and daytime alertness.

The study involved 2,297 adults with a mean age of 44 years; 51 per cent were male. Participants completed an online sleep health questionnaire and loneliness scale. The researchers analyzed the results using correlation and linear regression analyses along with moderation analyses.

In 2023 an advisory from the U.S. surgeon general warned about a public health crisis of loneliness, isolation, and lack of connection. It noted that even before the onset of the COVID-19 pandemic, approximately half of U.S. adults reported experiencing measurable levels of loneliness.

According to the authors, efforts and programs that aim to reduce loneliness should include an emphasis on promoting sleep health, especially in younger adults.

"Why younger adults might experience more sleep-related benefits to loneliness than older adults is unknown and intriguing -- certainly worth further investigation," Dzierzewski said.

May 30, 2024

Nicotine replacement therapy may help smokers quit by 70pc, cut withdrawal symptoms

Nicotine replacement therapy (NRT) is the new hope for smokers, as it can boost quit rates by 70 per cent while also helping reduce withdrawal symptoms, said experts here on Wednesday, ahead of World No-Tobacco Day.

Nicotine replacement therapy may help smokers quit by 70pc, cut withdrawal symptoms

World No-Tobacco Day is observed on May 31 every year and serves as a critical reminder of the ongoing battle against tobacco addiction.

Data shows that India is home to 266.8 million adult tobacco users, which includes cigarette, and bidi smokers as well as smokeless tobacco users buying products in loose form.

Nicotine is the primary addictive component in cigarettes, which delivers rapid pleasurable effects through smoking.

On the other hand, NRT acts as a temporary replacement for a small quantity of nicotine. It helps control cravings, alleviate withdrawal symptoms, and also facilitate the transition to tobacco abstinence.

Dr Nikhil Modi, Consultant - Critical Care, Respiratory Medicine & Sleep Disorder, Indraprastha Apollo Hospitals, New Delhi, told IANS that “nicotine is highly addictive, making quitting difficult. While nearly 70 per cent of smokers want to quit, only 3-5 per cent succeed”.

Unlike cigarettes, NRT provides a gradual and very small increase in blood nicotine levels, discouraging misuse. NRT aims to enable people to quit smoking with the help of nicotine delivery systems with reduced addictiveness.

“Without adequate cessation services, 160 million more smokers worldwide could die by 2050. Despite having 19 cessation centres in India, we still have the world's second-largest smoking population. It's time to move beyond stereotypes and adopt the successful strategies of other nations,” Dr Nikhil said.

Tobacco is a risk factor for health and is known to raise the risk of cancer, lung disease, heart disease, and stroke.

The widespread use of NRT by the US and some European countries has shown success. The experts called on India to overcome significant challenges in NRT awareness and accessibility to replicate these successes.

“NRT, available in various forms like patches, lozenges, inhalers, sprays, and gum, can increase quit rates by 50-70 per cent by alleviating withdrawal symptoms and cravings,” Dr Pawan Gupta, Senior Consultant, Department of Pulmonology, BLK MAX Hospital, New Delhi, told IANS.

He said quitting tobacco abruptly can lead to severe withdrawal symptoms, including headaches, insomnia, mood changes, and poor cognition.

“This is where non-tobacco substitutes play a crucial role. NRT is effective in reducing the urge to smoke gradually. Safer alternatives such as NRT have seen substantial success in countries such as the UK, Australia, the US, Canada, and France.”

“Ensuring the hassle-free availability and accessibility of NRT could greatly assist Indian smokers in quitting,” he added.

https://www.newkerala.com/news/2024/30536.htm

Menstrual hygiene management is need of the hour: ASSOCHAM CSR Council Chairperson

Anil Rajput, Chairperson, ASSOCHAM National CSR Council, addressed the gathering at the Menstrual Hygiene Management Conclave & Awards held in New Delhi on the occasion of Menstrual Hygiene Day, 2024.

Laying out the facts and figures around this matter of great importance, he said “The effectiveness of menstrual hygiene management continues to be an area that receives less than the desired attention. The National Family Health Survey indicates that around 22.7 per cent of women in India do not use hygienic methods for menstrual protection. Lack of access to menstrual hygiene facilities contributes to school absenteeism among girls, with around 23 per cent dropping out of school after reaching puberty. To address the same, the Government of India has been running a scheme for the promotion of menstrual hygiene among adolescent girls in the age group of 10-19 years in rural areas. However, amidst these challenges, there's a growing recognition of the need for innovative and impactful solutions to address menstrual hygiene effectively.”

The Menstrual Hygiene Conclave and Awards, aim to raise awareness, encourage innovation, and improve menstrual hygiene management, contributing to better health outcomes and reducing stigma around menstruation. The categories in which they were awarded include the most innovative product in menstrual hygiene, maximum impact by a CSR initiative in menstrual hygiene- Corporate/PSUs, maximum impact by a CSR initiative in menstrual hygiene- Implementing agency/NGO and MHM Champion of the Year.

Speaking on the need to create awareness and address the various taboos around this subject, Anil Rajput said: “Over the years, recognising the crucial need to break the silence and raise awareness about menstrual hygiene practices, as well as to combat menstrual stigma and create a supportive environment where every woman and girl can manage her menstruation hygienically, ASSOCHAM has been consistently organising conferences on the different aspects of menstrual health and awareness”.

Anil Rajput also underscored the need to double down on efforts in addressing the various facets of menstrual health and hygiene, He emphasised that “By highlighting exemplary efforts in this area, ASSOCHAM seeks to foster a supportive environment for menstrual health and hygiene, involving various stakeholders including businesses, NGOs, and government bodies. Let’s all redouble our efforts towards menstrual awareness and health and contribute towards building an even more resilient, participatory and powerful India.”

The government on its part has been playing a vital role in addressing this important subject as it has taken multiple steps to improve menstrual hygiene practices through the schemes/interventions of various Ministries/Departments.

The Ministry of Health and Family Welfare has implemented the Scheme for Promotion of Menstrual Hygiene since 2011 to increase awareness among adolescent girls, to increase access to and use of high-quality sanitary napkins to adolescent girls and to ensure safe disposal of Sanitary Napkins in an environmentally friendly manner.

Further, teachers and Frontline Workers - Auxiliary Nurse Midwives, Accredited Social Health Activist workers and Aanganwadi workers are oriented appropriately in the scheme with the budget provided for the same under Rashtriya Kishor Swasthya Karyakram. In addition, one of the objectives of Beti Bachao Beti Padhao (BBBP) components of ‘Misson Shakti’ is to generate awareness about menstrual hygiene and use of sanitary napkins.

Former Lieutenant Governor of Puducherry, Dr Kiran Bedi who was the chief guest at the event, called upon stakeholders to conduct extensive research to strengthen the menstrual health management system. She also made an appeal to all the awardees to join hands and identify areas in their region to work together and address this issue by creating a mass movement on this critical subject impacting a large number of girls and women in our country.

Addressing the Menstrual Hygiene Management Conclave, organised by ASSOCHAM in New Delhi, Dr Bedi said that policy intervention is extremely pivotal and emphasised that sanitary pads are also a necessity for women just like water and gas. Talking about the access to menstrual products in prisons, she expressed concern over the issue and called for immediate action.

https://www.newkerala.com/news/2024/30541.htm

CCMB, Aganitha to apply Generative AI for therapeutic design, research

The Centre for Cellular & Molecular Biology (CCMB) and Aganitha, a new generation 'in silico' solutions provider, signed a framework agreement to apply Generative Artificial Intelligence (AI) solutions for designing novel therapeutics and research tools addressing needs in multiple disease areas.

CCMB, a part of the Council of Scientific & Industrial Research (CSIR), and Aganitha, which combines the power of deep science and deep tech to bring novel medicines to market faster, signed an umbrella memorandum of understanding (MoU) to apply Aganitha’s Generative AI solutions for small molecule and antibody design for translation of CCMB’s R&D findings into therapeutic candidates.

Initial areas of collaboration include target analysis, small molecule design, and antibody and nanobody engineering for addressing malaria, tuberculosis (TB), and neurological disorders.

This strategic collaboration is designed to translate discoveries from the globally acclaimed research labs of CCMB into therapeutic candidates through the application of Aganitha’s Generative AI solutions for biopharma R&D, said a joint statement on Wednesday.

"We continue to struggle with controlling malaria due to drug resistance of the pathogen, lack of broadly available vaccines, and insecticide resistance of mosquitoes. Collaborative efforts of interdisciplinary experts are necessary to develop new drugs and vaccines for malaria. Towards this goal, we are leveraging Aganitha’s Generative AI capabilities in small molecules space for validated parasite drug targets to predict, test, and optimize potential antimalarial compounds," said Dr Puran Singh Sijwali, Senior Principal Scientist at CCMB.

Dr Raghunand Tirumalai, also a Senior Principal Scientist at the CCMB, said that they would work towards the structure-based discovery of small molecule inhibitors targeting essential proteins of Mycobacterium tuberculosis, adding that he expects this will lead to the identification of multiple novel anti-TB therapeutic leads.

"The collaboration between CSIR-CCMB and Aganitha to develop nanobody binders targeting a class of neurotransmitter receptors, called the GluD1 receptors, marks a significant stride in neuroscience and pharmacology. These nanobodies might serve as precise molecular tools to modulate GluD1 receptor activity, potentially unlocking novel therapeutic avenues for neurological disorders like Alzheimer's and epilepsy. With their small size and high specificity, nanobodies hold promise for targeted drug delivery and imaging applications, paving the way for tailored treatments with reduced side effects" said Dr Janesh Kumar, Senior Principal Scientist at CCMB.

"The collaboration with Aganitha is forward-looking, utilising CCMB’s strength in fundamental research on disease biology and Aganitha’s expertise in AI-driven solutions. It is timely for us to forge such a collaboration to take our lab leads towards more real-life solutions," CCMB Director Dr Vinay Nandicoori said.

Prasad Chodavarapu, co-founder and MD of Aganitha, sees the relationship between CCMB and Aganitha as a great example of the academia-industry collaboration needed to make a significant impact towards solving human diseases and suffering.

"We are a multi-disciplinary team of researchers specialising in multi-scale systems biology, quantum chemistry, and Generative AI, taking the here-and-now opportunity to leverage the virtual loop of innovation happening between Deep Science and Deep Tech, to transform global life sciences R&D," he said.

https://www.newkerala.com/news/2024/30564.htm

Tele-MANAS mental health helpline gets 3,500 calls per day: Centre

The Tele-MANAS toll-free number, launched as part of the national tele-mental health programme in India, receives 3,500 calls per day on average, the Ministry of Health and Family Welfare said on Wednesday.

Launched in October 2022, the 51 Tele-MANAS cells across all States and Union territories have since then received over 10 lakh calls, the health ministry said.

The toll-free helpline numbers 14416 or 1-800-891-4416, aimed at enhancing mental health service delivery nationwide, offers multi-language support and has been pivotal in facilitating communication between callers and mental health professionals.

As per the ministry, from around 12,000 in December 2022 to over 90,000 in May 2024, the helpline has seen a steady increase in the number of callers. It also incorporates call-backs for follow-up.

"This increase in engagement also underscores the importance of continued investment and expansion of mental health initiatives to ensure that everyone has access to the support they need," the ministry said.

"By linking existing mental health resources and establishing a comprehensive digital network, Tele-MANAS has become an essential platform for addressing the nation’s mental health needs," it added.

The ministry noted that providing teleservices to target vulnerable populations represents "a significant milestone in India's ongoing efforts to combat the mental health crisis".

The platform will also likely be integrated with initiatives like e-Sanjeevani to further enhance accessibility and effectiveness, the ministry said, noting that it will help address the rising mental health challenges in the country.

https://www.newkerala.com/news/2024/30565.htm

Light therapy helps in brain connectivity following injury

A study suggests that low-level light treatment may have an impact on the healing process in the brains of individuals who have experienced serious brain injuries.

The findings of the study were published in Radiology, a journal of the Radiological Society of North America (RSNA).

The ability of various wavelengths of light to heal wounds has been researched for many years. Low-level light treatment was used by researchers at Massachusetts General Hospital (MGH) on 38 patients who had experienced moderate traumatic brain injury, which is defined as a head injury severe enough to affect cognition and/or be detectable on a brain scan. Within 72 hours of their injury, patients underwent light therapy using a near-infrared light-emitting helmet.

"The skull is quite transparent to near-infrared light," said study co-lead author Rajiv Gupta, M.D., Ph.D., from the Department of Radiology at MGH. "Once you put the helmet on, your whole brain is bathing in this light."

The researchers used an imaging technique called functional MRI to gauge the effects of the light therapy. They focused on the brain's resting-state functional connectivity, the communication between brain regions that occurs when a person is at rest and not engaged in a specific task. The researchers compared MRI results during three recovery phases: the acute phase of within one week after injury, the subacute phase of two to three weeks post-injury and the late-subacute phase of three months after injury.

Of the 38 patients in the trial, 21 did not receive light therapy while wearing the helmet. This was done to serve as a control to minimize bias due to patient characteristics and to avoid potential placebo effects.

Patients who received low-level light therapy showed a greater change in resting-state connectivity in seven brain region pairs during the acute-to-subacute recovery phase compared to the control participants.

"There was increased connectivity in those receiving light treatment, primarily within the first two weeks," said study coauthor Nathaniel Mercaldo, Ph.D., a statistician with MGH. "We were unable to detect differences in connectivity between the two treatment groups long term, so although the treatment appears to increase the brain connectivity initially, its long-term effects are still to be determined."

The precise mechanism of the light therapy's effects on the brain is also still to be determined. Previous research points to the alteration of an enzyme in the cell's mitochondria (often referred to as the "powerhouse" of a cell), Dr. Gupta said. This leads to more production of adenosine triphosphate, a molecule that stores and transfers energy in the cells. Light therapy has also been linked with blood vessel dilation and anti-inflammatory effects.

"There is still a lot of work to be done to understand the exact physiological mechanism behind these effects," said study coauthor Suk-tak Chan, Ph.D., a biomedical engineer at MGH.

While connectivity increased for the light therapy-treated patients during the acute to subacute phases, there was no evidence of a difference in clinical outcomes between the treated and control participants. Additional studies with larger cohorts of patients and correlative imaging beyond three months may help determine the therapeutic role of light in traumatic brain injury.

The researchers expect the role of light therapy to expand as more study results come in. The 810-nanometer-wavelength light used in the study is already employed in various therapeutic applications. It's safe, easy to administer and does not require surgery or medications. The helmet's portability means it can be delivered in settings outside of the hospital. It may have applications in treating many other neurological conditions, according to Dr. Gupta.

"There are lots of disorders of connectivity, mostly in psychiatry, where this intervention may have a role," he said. "PTSD, depression, autism: these are all promising areas for light therapy."

https://www.newkerala.com/news/2024/30633.htm

Cut marks on 4,000-yr-old skulls show ancient Egyptians tried to treat cancer

The cut marks reveal the extent of traumatological and oncological treatments practised by ancient Egyptians

Cut marks on 4,000-yr-old skulls show ancient Egyptians tried to treat cancer

Ancient Egyptians attempted to operate on excessive tissue growth or learn more about cancerous disorders after a patient’s death, revealed a study on two 4,000-year-old skulls.

Known to be the place of one of the early civilisations, ancient Egyptians have been known to identify, describe, and treat diseases and traumatic injuries, build prostheses, and put in dental fillings.

To understand their further prowess, an international team of researchers studied two human skulls—male and female and each thousands of years old.

The cut marks on the skulls revealed the extent of traumatological and oncological treatments practised by the ancient Egyptians, they said in the paper published in the journal Frontiers in Medicine.

Edgard Camaros, a paleopathologist at the University of Santiago de Compostela in Spain called the discovery “unique and extraordinary” evidence of how ancient Egyptian medicine would have tried to deal with or explore cancer more than 4,000 years ago.

The two skulls—Skull and Mandible 236, dating from between 2687 and 2345 BCE, belonged to a male individual aged 30 to 35, while Skull E270, dating from between 663 and 343 BCE, belonged to a female individual who was older than 50 years.

Microscopic observation of skull 236 showed a big-sized lesion consistent with excessive tissue destruction, known as neoplasm.

Further, there were also 30 or so small and round metastasised lesions scattered across the skull, with cut marks probably made by a sharp object such as a metal instrument.

“When we first observed the cut marks under the microscope, we could not believe what was in front of us,” said Tatiana Tondini, a researcher at the University of Tubingen in Germany.

Analysis of Skull E270 also showed a big lesion consistent with a cancerous tumour that led to bone destruction, and two lesions from traumatic injuries that received treatment.

“This may indicate that although today’s lifestyle and cancer-causing substances in the environment increase cancer risk, it was also a common pathology in the past,” the team said. 

Studies show gene-based drugs to lower cholesterol in people with naturally high levels

According to researchers, drugs can be given to patients by injection four times a year

Studies show gene-based drugs to lower cholesterol in people with naturally high levels

Gene-based drugs could help lower cholesterol levels in patients with naturally high levels of the lipid in their blood, according to new studies published in the New England Journal of Medicine.

Researchers of the two studies said that the drugs can be given to patients by injection four times a year. The studies analyse the performance of two gene-based drugs plozasiran and zodasiran in early stage (phase-2b) clinical trials in terms of safety and efficacy.

These drugs are RNA-based, meaning they are made using small pieces of ribonucleic acid, which is present in all living organisms.

Formed from DNA, or deoxyribonucleic acid, RNA converts information present in DNA into proteins involved in all bodily functions and processes. The RNA material present in the drugs binds with the RNA naturally present in the body and prevents it from making proteins known to play roles in regulating ‘bad’ cholesterol levels, the researchers explained.

While plozasiran helps limit the formation of the protein apolipoprotein C3, zodasiran reduces the production of the protein angiopoietin-like 3 (ANGPTL3), according to the authors.

Both the drugs, developed by US-based Arrowhead Pharmaceuticals, were found to significantly lower triglyceride levels in patients with mixed hyperlipidemia, a congenital disease in which an individual has naturally higher levels of cholesterol and fat in their body. These patients were already taking cholesterol-lowering drugs, known as statins.

High triglyceride levels increase the chances of high ‘bad’ cholesterol in the body.

Plozasiran was trialled in a total of 353 participants, who were divided into cohorts. Two doses of 10 milligrams (mg), 25 mg, or 50 mg of plozasiran were administered once every 12 weeks or once every 24 weeks, the researchers said.

At week 24, triglyceride levels were found to have lowered by almost 50 per cent in the patients given the 10-mg-quarterly dose, whereas the levels were cut down by 56 per cent in the patients administered the 25-mg-quarterly dose.

Further, in the patients given the 50-mg quarterly dose, triglyceride levels fell by 62.4 per cent, while in the patients given the 50-mg-half-yearly dose, these levels fell by 44.2 per cent, the researchers found.

Zodasiran was trialled in a total of 204 participants. Eligible patients were randomly assigned to receive subcutaneous injections of the drug (50, 100, or 200 mg) or placebo on day 1 and week 12 and were followed through week 36.

At week 24, the researchers observed “substantial” lowering in levels of ANGPTL3 protein, lower levels of which are linked with lower levels of cholesterol.

“Other differences in change from the baseline as compared with placebo included the following: for non-HDL cholesterol level, minus 29 percentage points with 50 mg, minus 29 percentage points with 100 mg, and minus 36 percentage points with 200 mg; and for LDL cholesterol level, minus 16 percentage points, minus 14 percentage points, and minus 20 percentage points, respectively,” the authors wrote.

Zodasiran was also associated with lowered liver fat at week 24, with no adverse events related to liver function test changes reported so far, Arrowhead Pharmaceuticals said in a statement.

Further, plozasiran continued to show a favourable safety profile to date, according to the statement.

Arrowhead Pharmaceuticals develops RNA-based medicines for treating intractable diseases by silencing the genes that cause them, according to their website.

https://www.tribuneindia.com/news/health/studies-show-gene-based-drugs-to-lower-cholesterol-in-people-with-naturally-high-levels-626014

Early memory problems in cognitively healthy people linked to Alzheimer's risk

New research found that cognitively healthy people who self-reported memory problems had early signs of Alzheimer’s, such as high tau buildup in the brain.

  • A recent study found that cognitively healthy people who self-reported memory problems had early signs of Alzheimer’s in their brains.
  • The results may help experts detect Alzheimer’s sooner, allowing earlier treatment.
  • Starting treatment before symptoms begin is likely to be more effective.

A new study, published May 29 in Neurology, recruited neurologically healthy older adults without measurable cognitive impairments, but who had concerns about their memory.

The scientists looked for links between memory loss and signs of Alzheimer’s disease (AD). They found that people who self-reported memory loss were more likely to have elevated levels of proteins associated with Alzheimer’s.

If further research backs up these findings, it could help doctors catch the condition at an earlier stage, allowing treatment to start earlier.

Assessing cognition with memory and thinking skills

A team of researchers from Harvard Medical School recruited 675 older adults with an average age of 72.

First, participants took cognitive tests, which showed that they had no cognitive impairments.

Each recruit had a partner, which could be a child, spouse, or friend — 65% of these partners lived with the participant.

Participants answered questions about their memory and thinking skills and how well they performed daily tasks. Their partners also answered the same questions about the participants.

The questions included:

  • “Compared to 1 year ago, do you feel your memory has declined substantially?”
  • “Compared to 1 year ago, do you have more difficulty managing money?”

Brain scans reveal early signs of Alzheimer’s

Each participant underwent a brain scan to look for protein markers of Alzheimer’s disease called amyloid plaques and tau tangles.

Although the precise mechanisms that lead to Alzheimer’s disease are still being thrashed out, two telltale signs in the brain are associated with its progression:

  • Amyloid plaques —protein buildup between neurons
  • Tau tangles —protein buildup within neurons

Both of these limit cells’ ability to signal to each other. Eventually, this leads to cell death. Over time, as more cells die, it reduces cognitive ability and the brain can actually shrink or atrophy.

 

Medical News Today spoke with Verna Porter, MD, a board certified neurologist and director of Dementia, Alzheimer’s Disease and Neurocognitive Disorders at Pacific Neuroscience Institute in Santa Monica, CA.

Porter, who was not involved in the study, said these proteins “interfere with the formation of memories at both the biochemical level and structural level through interference with the physical integrity of neural networks. The patterns of impaired memory functions observed relate to changes in the structure and function of the brain.”

In the current study, 60% of participants had elevated levels of amyloid in the brain. People who have higher levels of amyloid are also more likely to have higher levels of tau.

Memory problems and protein buildup in Alzheimer’s

The brain scans showed that individuals with self-reported memory problems had higher levels of tau tangles. This association was even stronger in people who also had higher levels of amyloid.

In other words, people who experience memory problems are more likely to have neurological signs of Alzheimer’s despite being cognitively healthy.

MNT asked lead study author Rebecca E. Amariglio, PhD what surprised her most about the findings, she told us:

“Despite the fact that participants were cognitively unimpaired and functioning normally in their day-to-day, their study partners were still able to detect subtle changes in how they once were compared to a year ago that related to Alzheimer’s biomarkers.”

“Our study included a high percentage of people with elevated amyloid, and for this reason, we were able to also see that memory complaints were associated with higher tau tangles,” Amariglio explained in a press release.

“Our findings suggest that asking older people who have elevated Alzheimer’s disease biomarkers about subjective cognitive decline may be valuable for early detection,” she continued. “This is particularly important since it is predicted that treatments given at the earliest diagnosable form of the disease will be the most effective in slowing the disease.”

Speaking with MNT, Amariglio said that they plan to follow up this study with longitudinal data to understand how this relationship works over time.

What are the warning signs of Alzheimer’s?

MNT asked Porter about early Alzheimer’s signs to look out for. She explained that people should seek out care and a memory evaluation by a medical professional if they or a family member notices that someone is:

  • repetitively asking the same question
  • forgetting a word, phrase, or idea when speaking
  • inserting the wrong word in conversation, for instance, saying “chair” instead of “sofa”
  • taking longer to complete daily chores, tasks, or affairs, such as paying bills or managing the mail
  • frequently misplacing objects or items around the house
  • getting lost while walking or driving in a relatively familiar area
  • having sudden or unexplained changes in mood, personality, or behavior without a clear reason

Can dementia be prevented?

While a steady cognitive decline is often part of normal aging, Alzheimer’s and other dementias are not.

While we cannot influence some risk factors, such as our genetics and advancing age, some risk factors for dementia are modifiable.

MNT spoke with Iris Blotenberg, PhD, a postdoctoral researcher at the German Center for Neurodegenerative Diseases, who was not involved in the recent research. She explained that modifiable risk factors “are associated with at least one-third of dementia cases.” These factors include:

Blotenberg said that other health conditions can also increase the risk of developing dementia, such as “stroke, heart attack, high blood pressure, and obesity.”

 

As these conditions are more likely in people who are sedentary, smoke, and drink frequently, addressing these factors can make a real difference to an individual’s dementia risk.

Blotenberg added that hearing loss is a risk factor for dementia because “stimulation is very important for our brain to maintain cognitive function. Therefore, it is highly recommended to use a hearing aid if you or those around you notice a decline in hearing ability.”

Finally, social isolation — something that is increasingly common in Western societies — increases the risk of dementia.

“For us as social beings, social engagement is incredibly important and, not least, a vital form of stimulation for our brain,” Blotenberg said.

MNT also spoke with Geir Selbæk, a professor in the Department of Geriatric Medicine at the University of Oslo in Norway. Alongside the risk factors outlined above, he suggested people should “avoid head injury and areas with high levels of air pollution.”

Selbæk, who was not involved in the recent study, explained that stress may also be a risk factor. So, finding ways to minimize or deal with daily stresses could be helpful.

“In general, it is beneficial to start as early as possible and maintain a healthy lifestyle, but it is never too late,” Blotenberg said.

“It is always good to continue to be cognitively active — stimulation is crucial for our brain. Therefore, within your means, stay cognitively, socially, and physically active, but be careful not to overextend yourself,” she concluded.

https://www.medicalnewstoday.com/articles/first-signs-of-memory-problems-brain-changes-alzheimers#Can-dementia-be-prevented?